Novartis: CHMP grants positive opinion for Sandoz biosimilar
(CercleFinance.com) - Novartis' Sandoz has said that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given marketing authorization of its proposed biosimilar to infliximad, a widely-used treatment of autoimmune conditions.
The CHMP opinion recommends the proposed biosimilar for the treatment of all indications of its reference medicine across gastroenterology, rheumatology and dermatology, Sandoz said.
Infliximab - also known as Remicade, Inflectra or Remsima - is used to treat Crohn's disease, psoriasis, and rheumatoid polyarthritis.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The CHMP opinion recommends the proposed biosimilar for the treatment of all indications of its reference medicine across gastroenterology, rheumatology and dermatology, Sandoz said.
Infliximab - also known as Remicade, Inflectra or Remsima - is used to treat Crohn's disease, psoriasis, and rheumatoid polyarthritis.
Copyright (c) 2018 CercleFinance.com. All rights reserved.